xCures has closed a $46 million Series B led by Innovius Capital, with participation from iGrow, Spring Mountain Capital and existing backers, according to Crunchbase News. The round more than doubled the company's valuation to $127 million post-money -- up from the $25 million Series A it raised in December 2023 -- and brings total funding to more than $76 million since its 2018 founding as a spinout of Cancer Commons.
The company's platform tackles one of healthcare's most stubborn problems: patient records are scattered across thousands of incompatible systems, formats and providers, making them nearly unusable for clinical decisions or research. xCures uses AI to ingest that chaos -- it has processed more than 300 million medical records from over 550,000 healthcare locations -- and convert it into structured, decision-ready clinical data for hospitals, diagnostic labs and telehealth providers.
“Notably, management framed the raise as an intentional capital-burn phase to build its team for a 2027 pipeline, a deliberate trade of near-term profitability for scale.”
The financial profile is unusually disciplined for an AI company. Led by CEO Mika Newton, xCures grew annual recurring revenue from roughly $3 million to $10 million in 2025, reached cash-flow breakeven, and is on track for $20 million ARR in 2026. Its 25 enterprise customers include oncology heavyweights Exact Sciences, Caris Life Sciences and Novocure -- a customer roster that validates real, paid demand rather than pilots.
The round sits in a crowded but real category. Health-data structuring and clinical-AI plays -- from Abridge and Commure to Tempus on the genomics-data side -- have drawn heavy investment, but xCures' edge is its breakeven discipline and its depth in oncology, where messy longitudinal records carry the highest stakes. Notably, management framed the raise as an intentional capital-burn phase to build its team for a 2027 pipeline, a deliberate trade of near-term profitability for scale.
What to watch: whether xCures can hit $20M ARR in 2026 while ramping spend, whether it expands beyond oncology, and how it defends its data moat as foundation-model vendors push into clinical record structuring.